➤ Patients at risk for CTIBL should adopt lifestyles that preserve bone health, including smoking cessation, moderate alcohol consumption, weight-bearing exercise, adequate calcium and vitamin D intake, and measures to prevent falls.
➤ Bisphosphonates are the most effective therapies for patients with CTIBL. IV bisphosphonates are more potent, better tolerated, and less frequently administered than oral bisphosphonates. Data Synthesis: CTIBL is a long-term complication associated with cancer therapies that cause hypogonadism in patients with breast or prostate cancer. Early diagnosis and treatment of CTIBL is essential to prevent bone fractures. CTIBL treatment includes modifi cation of lifestyles that increase the risk of developing bone loss and fractures and includes the use of bone loss therapies (e.g., bisphosphonates, selective estrogen receptor modifi ers, calcitonin).
CONTINUING EDUCATION
Conclusions: CTIBL is becoming more common as patients with breast or prostate cancer survive longer. Identifying and treating CTIBL early are important because once bone is lost, damaged bone becomes more diffi cult to repair; early diagnosis and treatment also may prevent fractures.
Implications for Nursing: Nurses must be knowledgeable about CTIBL to identify high-risk patients and educate patients and their families about CTIBL, bone loss therapies, and lifestyle modifi cations.
Goal for CE Enrollees:
To enhance nurses' knowledge about cancer treatmentinduced bone loss (CTIBL) in people with breast or prostate cancer.
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